DBV Technologies (France)

Teleoperation is emerging as a key enabler for deploying automated vehicles in safety-critical environments where full autonomy is not yet feasible. Ensuring safety in such systems is challenging due to their reliance on, for example, human operators, wireless communication networks, mixed-traffic interactions, and onboard automated systems, as well as the interdependencies among these components that can trigger cascading failures. To address this, we present a case study on the safety analysis of teleoperated driving in underground mines. We model the teleoperation architecture using a Dynamic Fault Tree (DFT), an extension of traditional static fault trees with explicit modeling support for functional dependencies, order-dependent failures, and redundancy mechanisms. The DFT model is rigorously evaluated through probabilistic model checking across a broad range of system-wide metrics, including degradation behavior and criticality of components. The results provide insights into system reliability, the sensitivity of failure probabilities with respect to different component failure rates, and the behavior of the system in fully functional, fail-operational, and degraded modes. Overall, the findings highlight the critical components that dictate system dependability and establish a structured basis for enhancing the safety of teleoperated vehicle systems to comply with industrial safety standards.

This study investigates the use of industrial-grade polydimethylsiloxane (PDMS) for mass production of microfluidic chips through Liquid Silicone Rubber Injection Molding (LSR-IM) technologies. Injection molding of PDMS is ubiquitous in the automotive and aerospace industries. Yet, it is not currently applied to large-scale production of microfluidic devices. Here, we manufactured PDMS microfluidics devices using industrial IM systems and measured the values of several physicochemical properties of PDMS important in microfluidics. For the two grades of injection-moldable PDMS studied, properties were found close to those of the standard Sylgard 184 PDMS, except Young’s modulus, which varied from 66% to 250% of the Sylgard 184 value and the absorption of small molecules, which was lower or equal to that within Sylgard 184. Yet, the main benefits of LSR-IM production lie in its systematic process, resulting in an increase in reproducibility of both PDMS surface and bulk properties by decreasing the variance within and between production batches of several variables: Young’s modulus (30-fold), oxygen permeation (10-fold), mean fluorescence intensity of Nile Red (5-fold). Emphasis on biocompatibility of LSR-IM was evaluated by culturing complex and sensitive 3D biology models (tumor spheroids and explants) in injection-molded PDMS devices. We observed no significant differences in cell proliferation relative to samples cultured on conventional Sylgard 184 PDMS devices. Overall, these findings open a direct path from benchtop prototyping to industrialization of PDMS-based microfluidic devices for applications in healthcare.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-16863-z.

We introduce a generalized Dual-Probe imaging system integrating in a unified platform both Infra-Red (IR) and Thermoreflectance (TR) lenses featuring coated-patterning. A dedicated, diffusion-aware, calibration-kit (CK) with a scalable array of resizable grid, seen as collectively interacting patterned unit-cells under random-field fluctuations, is introduced. Powered by an adaptive biasing DC supply, the CK module includes standard connectivity for easy interfacing through a simple command set, making it compatible with standard programming environments (e.g., Matlab, C, Python, Labview, and others). With PID control technology, it guarantees real-time temperature compensation as a function of airflow. The module also offers a user-friendly graphical interface to ensure an effortless setup process for facilitating a parametric AI-powered database creation and indexation for thermal-visual image identification and cross-correlations targeting advanced multi-physics characterization and industrial-testing applications. The proposed multi-probing system, referenced as “Cognitive-Lens”, integrates correlation-based signal processing powered by physics-informed AI algorithms for creating real-time instruments and tools applicable to noise and variation-aware on-the-move imaging applications. Perspectives are drawn for Multi-Scale and Super-Resolution technologies with sub-micron spatial resolution (beyond diffraction limit).

This paper presents a wideband two-stage low-noise amplifier (LNA) covering continuously from 21 GHz up to 47 GHz. The design employs a feedback technique using a transformer-based network at the input common-source stage which introduces poles and manipulates Γ<inf xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">opt</inf> (by modifying the noise correlations between the input and output), allowing for an eased implementation of simultaneous power- and noise-match over a wide band. The design was fabricated in the low power 22 nm FD-SOI node from GlobalFoundries. At nominal bias, the measured LNA achieves a gain of 15.5 dB over the entire K- and Ka-bands with 2-dB-ripple, and a minimum noise figure of 2.2 dB for 9.1 mW of power. The bias point can also be effectively modulated through the use of back-gate biasing, allowing overall for more than 10 dB of gain-control.

Zusammenfassung Es gibt keinen Konsens über die Beschreibung und Schweregradeinteilung allergischer Nebenwirkungen bei Immuntherapien, obwohl zumindest hinsichtlich der Verwendung der Klassifikationssysteme der World Allergy Organisation (WAO) zur Beschreibung lokaler unerwünschter Ereignisse bei sublingualer Immuntherapie (SLIT) und systemischer allergischer Reaktionen (SAR) bei subkutaner Immuntherapie (SCIT) ein Konsens zwischen den wichtigsten nationalen/regionalen Allergiegesellschaften zu bestehen scheint. In diesem Artikel wird eine Modifikation des bestehenden WAO-Klassifikationssystems für SAR vorgeschlagen, die mit der neu vorgeschlagenen Klassifikationsskala des Consortium for Food Allergy Research (CoFAR) für systemische allergische Reaktionen bei Lebensmittelallergien (Version 3.0) übereinstimmt. Wir hoffen, dass damit ein einheitliches Klassifikationssystem zur Verfügung steht, das für Berichte über unerwünschte Reaktionen auf eine Allergen-Immuntherapie unabhängig vom Allergen und Verabreichungsweg sowohl in der klinischen Praxis als auch in der Forschung geeignet ist.

Peanut allergy treatment options remain limited, but novel approaches are being studied, including epicutaneous immunotherapy (EPIT). EPIT uses the cutaneous immune system to promote tolerance to food allergens. Viaskin Peanut, an approach to EPIT in late-stage clinical development uses an occlusive patch with a condensation chamber that enables natural epidermal water loss to solubilize dry antigen on the patch, which is then absorbed and captured by skin dendritic cells. This form of EPIT does not require disruption of the skin barrier, thus avoiding a proinflammatory cytokine response by targeting the non-vascularized epidermis and limiting systemic allergen exposure. Extensive preclinical research suggests that Viaskin Peanut has a distinct mechanism of desensitization, including the potential for disease modification, driven by a unique population of regulatory T cells. Numerous clinical studies of Viaskin Peanut have demonstrated desensitization and reductions in reaction severity, particularly in children aged 1 through 11 years, as well as a favorable safety profile with mostly mild to moderate skin reactions that were observed to decrease over time. EPIT with Viaskin Peanut may be a potential therapeutic option for peanut allergy that is clinically practical with long-term efficacy and tolerability.

ABSTRACT Introduction DBV712 250 µg (also referred to as Viaskin Peanut or peanut patch; Viaskin is a trademark of DBV Technologies) is an innovative approach to epicutaneous immunotherapy (EPIT). The patch-based technology system facilitates peanut protein (allergen) absorption into the intact non-vascularized epidermis to promote desensitization to peanut while limiting systemic allergen exposure. Areas Covered Efficacy and safety in children have been evaluated in four completed phase 3 studies. Overall, the results from these studies have demonstrated the peanut patch to be superior in desensitization compared with placebo and safe for daily use over multiple years. Expert Opinion These findings, as well as supportive evidence from phase 2 studies, confirm the potential for an effective treatment of peanut allergy in children. The purpose of this review is to summarize the safety and efficacy of the peanut patch in the treatment of peanut allergy.

This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3years. The patch is a form of epicutaneous immunotherapy (EPIT), which is a new approach to allergen immunotherapy that delivers a small amount of peanut protein to the immune system through the skin. Viaskin Peanut is an investigational therapy, meaning it has not yet been approved by the United States Food and Drug Administration (FDA), that has been studied before in young children aged 4 through 11years. In those studies, the children who received the patch were desensitized and were less likely to experience anaphylaxis when they ate peanut at the end of the study. The EPITOPE study included children aged 1 through 3years with peanut allergy and looked at how well the peanut patch worked and how safe it was compared to a patch with no medicine (placebo, no medicine) after 12months. The study showed that the peanut patch was better in desensitizing children to peanuts than the placebo patch. Most of the children in the study who received the peanut patch for 12months (the treatment group) were able to eat and tolerate more peanut at the end of the study than those who received only the placebo patch (the control group). This demonstrates that the children in the treatment group were less likely to have an allergic reaction if they ate peanut by accident at the end of the study. The children in the treatment group also had less severe symptoms when they were given peanut during the oral food challenges at the end of the study. Most children in both groups experienced side effects. Mild to moderate local skin reactions where the patch was applied were most common. These side effects happened less often and were less serious over the 12-month treatment period. Overall, these results show the peanut patch may be a possible treatment option to help desensitize young children with peanut allergy to peanut.